Literature DB >> 21062665

For severe malaria, artesunate is the answer.

G Dennis Shanks1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21062665     DOI： 10.1016/S0140-6736(10)61928-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013.

Authors:  Stéphane Jauréguiberry; Marc Thellier; Papa Alioune Ndour; Flavie Ader; Camille Roussel; Romain Sonneville; Julien Mayaux; Sophie Matheron; Adela Angoulvant; Benjamin Wyplosz; Christophe Rapp; Thierry Pistone; Bénédicte Lebrun-Vignes; Eric Kendjo; Martin Danis; Sandrine Houzé; François Bricaire; Dominique Mazier; Pierre Buffet; Eric Caumes
Journal:  Emerg Infect Dis       Date:  2015-05       Impact factor: 6.883

2.  Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line.

Authors:  Liang Liu; Lian Fu Zuo; Jian Wen Guo
Journal:  Oncol Lett       Date:  2013-08-23       Impact factor: 2.967

Review 3.  Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis.

Authors:  Paulina Sypniewska; Jose F Duda; Isabella Locatelli; Clotilde Rambaud Althaus; Fabrice Althaus; Blaise Genton
Journal:  BMC Med       Date:  2017-08-03       Impact factor: 8.775
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.